William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Health sector stocks fluctuate amid DOJ probe into UnitedHealth (UNH), Gilead upgrade for HIV treatments, and Moderna's focus on non-COVID approvals.

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in ...

Sanofi and J&J discontinued E.mbrace phase 3 study after the vaccine showed insufficient efficacy in preventing invasive E. coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 ...

Sanofi said it would discontinue its phase 3 clinical trial for an E. Coli vaccine after a review by an independent data monitoring committee. The French pharma company said the scheduled review ...

Credit: Shutterstock / Saiful52. Johnson and Johnson (J&J) has announced the cancellation of its Phase III E.mbrace study examining Sanofi’s investigational vaccine for extraintestinal pathogenic ...

L’Oreal OR0.83%increase; green up pointing triangle will sell part of its stake in Sanofi SAN-0.46%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...